Effects of the phosphodiesterase 2 inhibitor BI 474121 on central nervous system cyclic guanosine monophosphate concentrations: Translational studies
British Journal of Clinical Pharmacology · 2024
DOI: 10.1111/bcp.16137 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift British Journal of Clinical Pharmacology, 2024. Verfasst von Sebastiaan van Kraaij und 7 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Human Drug Research, Leiden, Netherlands. Hauptthemen laut MEDLINE: Cyclic GMP, Cyclic Nucleotide Phosphodiesterases, Type 2, Dose-Response Relationship, Drug. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Boehringer Ingelheim.
Abstract (Originalsprache)
Aims
Phosphodiesterase 2 (PDE2) regulates intracellular cyclic adenosine monophosphate and guanosine monophosphate (cAMP/cGMP) levels, which contribute to processes crucial for learning and memory. BI 474121, a potent and selective PDE2 inhibitor, is in development for treating cognitive impairment associated with schizophrenia.
Methods
The effects of BI 474121 on cGMP concentrations were first assessed in rat cerebrospinal fluid (CSF) to demonstrate central nervous system (CNS) and functional target engagement. Next, a Phase I study in healthy participants assessed the pharmacokinetics of BI 474121 in CSF vs . plasma, the pharmacodynamics of BI 474121 by measuring cGMP concentrations in the CSF, and the safety of BI 474121.
Results
In rats, BI 474121 was associated with a dose‐dependent increase (71% at the highest dose tested [3.0 mg kg −1 ]) in cGMP levels in the CSF relative to vehicle ( P < 0.001). In healthy participants, the maximum‐measured concentration CSF‐to‐plasma ratio for BI 474121 exposure was similar following single oral doses of BI 474121 2.5, 10, 20 and 40 mg (dose‐adjusted geometric mean: 8.96% overall). BI 474121 2.5–40 mg administration in healthy participants also increased cGMP levels in CSF (maximum exposure‐related change from baseline ratio, BI 474121: 1.44–2.20 vs . placebo: 1.26). The most common treatment‐emergent adverse event (AE) was mild‐to‐moderate post‐lumbar puncture syndrome, which resolved with standard treatment. No AEs of special interest were observed.
Conclusions
BI 474121 crosses the blood–brain barrier to inhibit PDE2, supporting cGMP as a translational marker to monitor CNS target engagement. These findings promote further clinical development of BI 474121. ClinicalTrials.gov number (NCT04672954).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Human Drug Research, Leiden, Netherlands.
- Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany.
ORCID-Profile: Sebastiaan van Kraaij, Geert Jan Groeneveld, Christian Schultheis
Förderung
- Boehringer Ingelheim
Zitieren
APA
van Kraaij, S., Goeldner, R. G., Rosenbrock, H., Groeneveld, G. J., Kremer, P., Schaible, J., Zambori, J., & Schultheis, C. (2024). Effects of the phosphodiesterase 2 inhibitor BI 474121 on central nervous system cyclic guanosine monophosphate concentrations: Translational studies. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16137
Vancouver
van Kraaij S, Goeldner RG, Rosenbrock H, Groeneveld GJ, Kremer P, Schaible J, et al. Effects of the phosphodiesterase 2 inhibitor BI 474121 on central nervous system cyclic guanosine monophosphate concentrations: Translational studies. British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.16137
BibTeX
@article{vanKraaij2024,
author = {van Kraaij, Sebastiaan and Goeldner, Rainer-Georg and Rosenbrock, Holger and Groeneveld, Geert Jan and Kremer, Philip and Schaible, Jennifer and Zambori, Janos and Schultheis, Christian},
title = {Effects of the phosphodiesterase 2 inhibitor BI 474121 on central nervous system cyclic guanosine monophosphate concentrations: Translational studies},
journal = {British Journal of Clinical Pharmacology},
year = {2024},
doi = {10.1111/bcp.16137}
}
EUVIMED